<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39260435</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Neoadjuvant Immunotherapy Alone for Patients With Locally Advanced and Resectable Metastatic Colorectal Cancer of dMMR/MSI-H Status.</ArticleTitle><Pagination><StartPage>1413</StartPage><EndPage>1422</EndPage><MedlinePgn>1413-1422</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003290</ELocationID><Abstract><AbstractText Label="BACKGROUND">The use of programmed death-1 blockade has a significant therapeutic effect in patients with mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. However, data on preoperative single-agent programmed death-1 blockade are rare.</AbstractText><AbstractText Label="OBJECTIVE">This study aims to evaluate the effectiveness and safety of preoperative programmed death-1 blockade as a conversion strategy in patients with locally advanced and resectable metastatic mismatch repair-deficient/microsatellite instability-high colorectal cancer.</AbstractText><AbstractText Label="DESIGN">This is a retrospective observational study.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a high-volume tertiary referral cancer center in China.</AbstractText><AbstractText Label="PATIENTS">Twenty-four patients of consecutive cases since 2020 to 2022 with mismatch repair-deficient/microsatellite instability-high colorectal cancer who received preoperative single-agent programmed death-1 blockade were retrospectively reviewed. These patients had either bulking tumors scheduled for multivisceral resection, a strong desire for organ preservation, or potentially resectable metastatic lesions.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Pathological complete response, clinical complete response, toxicity, R0 resection rate, and complications were evaluated.</AbstractText><AbstractText Label="RESULTS">Patients tolerated preoperative immunotherapy well. The R0 resection rate was 95.2%, and the pathological complete response rate was 47.6%. Three patients (12.5%) were evaluated as having a clinical complete response and then underwent "watch and wait." One-half of the patients with cT4b were spared multivisceral resection, whereas 60% (3/5) achieved pathological complete response. All 3 patients with liver metastases obtained complete response of all liver lesions after programmed death-1 blockade treatment. Grade III postoperative complications occurred in 2 patients.</AbstractText><AbstractText Label="LIMITATIONS">The limitations of this study are as follows: retrospective study, small sample size, and short follow-up.</AbstractText><AbstractText Label="CONCLUSIONS">Preoperative anti-programmed death-1 therapy alone as a conversion strategy in initially resected difficult mismatch repair-deficient/microsatellite instability-high colorectal cancer can achieve a high tumor complete response. The use of immunopreoperative therapy in patients with T4b colon cancer or low rectal cancer can reduce multivisceral resection and achieve high organ function preservation. See the Video Abstract .</AbstractText><AbstractText Label="INMUNOTERAPIA NEOADYUVANTE SOLA PARA PACIENTES CON CNCER COLORRECTAL LOCALMENTE AVANZADO Y METASTSICO RESECABLE CON ESTADO DMMR/MSIH">ANTECEDENTES:El uso del bloqueo de muerte programada-1 tiene un efecto terap&#xe9;utico significativo en pacientes con c&#xe1;ncer colorrectal metast&#xe1;sico deficiente en reparaci&#xf3;n de desajustes/inestabilidad de microsat&#xe9;lites-alta (dMMR/MSI-H). Sin embargo, los datos sobre el bloqueo preoperatorio de muerte programada-1 con un solo agente son escasos.OBJETIVO:Este estudio tiene como objetivo evaluar la eficacia y seguridad del bloqueo preoperatorio de muerte programada-1 como estrategia de conversi&#xf3;n en pacientes con c&#xe1;ncer colorrectal localmente avanzado y metast&#xe1;sico resecable con dMMR/MSI-H.DISE&#xd1;O:Este es un estudio observacional retrospectivo.ESCENARIO:Este estudio se realiz&#xf3; en un centro oncol&#xf3;gico terciario de referencia de gran volumen en China.PACIENTES:Se revisaron retrospectivamente veinticuatro pacientes de casos consecutivos desde 2020-2022 con c&#xe1;ncer colorrectal y dMMR/MSI-H que recibieron bloqueo preoperatorio de muerte programada-1 con un solo agente. Estos pacientes ten&#xed;an un tumor voluminoso programado para resecci&#xf3;n multivisceral, un fuerte deseo de preservaci&#xf3;n del &#xf3;rgano o lesiones metast&#xe1;sicas potencialmente resecables.PRINCIPALES MEDIDAS DE RESULTADO:Se evaluaron la respuesta patol&#xf3;gica completa, la respuesta cl&#xed;nica completa, la toxicidad, la tasa de resecci&#xf3;n R0 y las complicaciones.RESULTADOS:Los pacientes toleraron bien la inmunoterapia preoperatoria. La tasa de resecci&#xf3;n R0 fue del 95,2% y la tasa de respuesta patol&#xf3;gica completa fue del 47,6%. Tres pacientes (12,5%) fueron evaluados como respuesta cl&#xed;nica completa y luego sometidos a "observar y esperar". La mitad de los pacientes cT4b se salvaron de la resecci&#xf3;n multivisceral, mientras que el 60% (3/5) lograron una respuesta patol&#xf3;gica completa. Los tres pacientes con met&#xe1;stasis hep&#xe1;ticas obtuvieron respuesta completa de todas las lesiones hep&#xe1;ticas despu&#xe9;s del tratamiento de bloqueo de muerte programada-1. En dos pacientes se produjeron complicaciones postoperatorias de grado III.LIMITACIONES:Las limitaciones de este estudio son las siguientes: estudio retrospectivo, tama&#xf1;o de muestra peque&#xf1;o y seguimiento corto.CONCLUSIONES:La terapia preoperatoria anti muerte programada-1 sola como estrategia de conversi&#xf3;n en el c&#xe1;ncer colorrectal inicialmente dif&#xed;cil de resecar con dMMR/MSI-H puede lograr una alta respuesta completa tumoral. El uso de terapia inmunopreoperatoria en pacientes con c&#xe1;ncer de colon T4b o c&#xe1;ncer de recto bajo puede reducir la resecci&#xf3;n multivisceral y lograr una alta preservaci&#xf3;n de la funci&#xf3;n del &#xf3;rgano. (Traducci&#xf3;n-Dr. Felipe Bellolio ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yingjie</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6091-8911</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Gastrointestinal Cancer Center, Unit III, Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Luxin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Gastrointestinal Cancer Center, Unit III, Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xinzhi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Gastrointestinal Cancer Center, Unit III, Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Yunfeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Gastrointestinal Cancer Center, Unit III, Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiology, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Aiwen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Gastrointestinal Cancer Center, Unit III, Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZYLX202116</GrantID><Agency>Beijing Hospitals Authority Clinical Medicine Development of Special Funding</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053842" MajorTopicYN="Y">Microsatellite Instability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053843" MajorTopicYN="N">DNA Mismatch Repair</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>12</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>11</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39260435</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003290</ArticleId><ArticleId IdType="pii">00003453-202411000-00009</ArticleId></ArticleIdList><ReferenceList><Title/><Reference><Citation>Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073&#x2013;2087.e3.</Citation></Reference><Reference><Citation>Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer. Front Oncol. 2019;9:396.</Citation></Reference><Reference><Citation>Giannakis M, Mu XJ, Shukla SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;15:857&#x2013;865.</Citation></Reference><Reference><Citation>Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43&#x2013;51.</Citation></Reference><Reference><Citation>Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30:1232&#x2013;1243.</Citation></Reference><Reference><Citation>Gebhardt C, Meyer W, Ruckriegel S, Meier U. Multivisceral resection of advanced colorectal carcinoma. Langenbecks Arch Surg. 1999;384:194&#x2013;199.</Citation></Reference><Reference><Citation>Mohan HM, Evans MD, Larkin JO, Beynon J, Winter DC. Multivisceral resection in colorectal cancer: a systematic review. Ann Surg Oncol. 2013;20:2929&#x2013;2936.</Citation></Reference><Reference><Citation>Seymour MT, Morton D; on behalf of the International FOxTROT Trial Investigators. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol. 2019;37(suppl):3504&#x2013;3504.</Citation></Reference><Reference><Citation>Hasan S, Renz P, Wegner RE, et al. Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: a national cancer database (NCDB) analysis. Ann Surg. 2020;271:716&#x2013;723.</Citation></Reference><Reference><Citation>Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509&#x2013;2520.</Citation></Reference><Reference><Citation>Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38:11&#x2013;19.</Citation></Reference><Reference><Citation>Le DT, Diaz L, Kim TW, et al. 432P Pembrolizumab (pembro) for previously treated, microsatellite instability&#x2013;high (MSI-H)/mismatch repair&#x2013;deficient (dMMR) metastatic colorectal cancer (mCRC): final analysis of KEYNOTE-164. Ann Oncol. 2021;32:S550.</Citation></Reference><Reference><Citation>Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182&#x2013;1191.</Citation></Reference><Reference><Citation>Lenz H-J, Lonardi S, Zagonel V, et al. Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): two-year clinical update. J Clin Oncol. 2020;38(suppl):4040&#x2013;4040.</Citation></Reference><Reference><Citation>Andr&#xe9; T, Shiu K-K, Kim TW, et al.; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207&#x2013;2218.</Citation></Reference><Reference><Citation>Diaz LA, Shiu K-K, Kim T-W, et al.; KEYNOTE-177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23:659&#x2013;670.</Citation></Reference><Reference><Citation>Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26:566&#x2013;576.</Citation></Reference><Reference><Citation>Chalabi M, Verschoor YL, van den Berg J, et al. LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study. Ann Oncol. 2022;33:S1389.</Citation></Reference><Reference><Citation>Hu H, Kang L, Zhang J, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:38&#x2013;48.</Citation></Reference><Reference><Citation>Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. Chicago: Springer; 2017.</Citation></Reference><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:874&#x2013;901.</Citation></Reference><Reference><Citation>Seymour L, Bogaerts J, Perrone A, et al.; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143&#x2013;e152.</Citation></Reference><Reference><Citation>Smith JJ, Strombom P, Chow OS, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5:e185896.</Citation></Reference><Reference><Citation>Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. 2012;67:1025&#x2013;1039.</Citation></Reference><Reference><Citation>Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187&#x2013;196.</Citation></Reference><Reference><Citation>Hoffmann M, Phillips C, Oevermann E, et al. Multivisceral and standard resections in colorectal cancer. Langenbecks Arch Surg. 2012;397:75&#x2013;84.</Citation></Reference><Reference><Citation>Demisse R, Damle N, Kim E, et al. Neoadjuvant immunotherapy-based systemic treatment in MMR-deficient or MSI-high rectal cancer: case series. J Natl Compr Canc Netw. 2020;18:798&#x2013;804.</Citation></Reference><Reference><Citation>Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363&#x2013;2376.</Citation></Reference><Reference><Citation>Wolmark N, Wieand HS, Rockette HE, et al. The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg. 1983;198:743&#x2013;752.</Citation></Reference><Reference><Citation>Chen HS, Sheen-Chen SM. Obstruction and perforation in colorectal adenocarcinoma: an analysis of prognosis and current trends. Surgery. 2000;127:370&#x2013;376.</Citation></Reference><Reference><Citation>Wang Q, Gao J, Wu X. Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol. 2018;58:125&#x2013;135.</Citation></Reference><Reference><Citation>Zheng J, Huang B, Nie X, Zhu Y, Han N, Li Y. The clinicopathological features and prognosis of tumor MSI in East Asian colorectal cancer patients using NCI panel. Future Oncol. 2018;14:1355&#x2013;1364.</Citation></Reference><Reference><Citation>Bai W, Ma J, Liu Y, et al. Screening of MSI detection loci and their heterogeneity in East Asian colorectal cancer patients. Cancer Med. 2019;8:2157&#x2013;2166.</Citation></Reference><Reference><Citation>Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10:293&#x2013;300.</Citation></Reference><Reference><Citation>Wang Z, Zhao J, Wang G, et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade. Cancer Res. 2018;78:6486&#x2013;6496.</Citation></Reference><Reference><Citation>McGrail DJ, Pili&#xe9; PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32:661&#x2013;672.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35195557</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Prognostic Significance of Systemic Inflammation Indices by K-ras Status in Patients With Metastatic Colorectal Cancer.</ArticleTitle><Pagination><StartPage>e809</StartPage><EndPage>e817</EndPage><MedlinePgn>e809-e817</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002392</ELocationID><Abstract><AbstractText Label="BACKGROUND">Systemic inflammation markers are useful prognostic indicators for metastatic colorectal cancer. However, the influence of K-ras genotypes on these markers in patients with metastatic colorectal cancer is unclear.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to evaluate the associations between systems of evaluating pretreatment systemic inflammation and outcomes according to K-ras genotypes in patients with metastatic colorectal cancer.</AbstractText><AbstractText Label="DESIGN">This was a retrospective study.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a university hospital.</AbstractText><AbstractText Label="PATIENTS">This study included a total of 272 patients ( K-ras wild type: K-ras mutant = 169:103) who received first-line systemic chemotherapy for metastatic colorectal cancer.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">We retrospectively calculated 8 systemic inflammation indices: neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, lymphocyte/monocyte ratio, prognostic nutritional index, Glasgow prognostic score, Naples prognostic score, systemic inflammation score, and systemic immune-inflammation index. Patients were categorized into high or low groups for each index. The prognostic relevance of these indices for overall survival was evaluated according to the K-ras genotype.</AbstractText><AbstractText Label="RESULTS">Kaplan-Meier survival analyses showed that median overall survival significantly differed between the high and low groups for all indices in the K-ras wild-type group but not in the K-ras mutant group, except for Glasgow prognostic score and lymphocyte/monocyte ratio. Multivariate Cox regression analyses identified all indices as independent prognostic factors. In the K-ras wild-type group, all indices except platelet/lymphocyte ratio had strong prognostic effects, but not in the K-ras mutant group. Interaction tests indicated that K-ras genotype significantly influenced the prognostic impacts of the neutrophil/lymphocyte ratio ( p = 0.042), prognostic nutritional index ( p = 0.048), Naples prognostic score ( p &lt; 0.001), and systemic immune-inflammation index ( p = 0.004).</AbstractText><AbstractText Label="LIMITATIONS">A major limitation of this study is the lack of external validation.</AbstractText><AbstractText Label="CONCLUSIONS">The prognostic significance of systemic inflammation indices is more useful in patients with K-ras wild-type metastatic colorectal cancer than those with K-ras mutant cancer. See Video Abstract at http://links.lww.com/DCR/B921 .</AbstractText><AbstractText Label="IMPORTANCIA PRONSTICA DE LOS NDICES DE INFLAMACIN SISTMICA POR ESTADO DE KRAS EN PACIENTES CON CNCER COLORRECTAL METASTSICO">ANTECEDENTES:Los marcadores de inflamaci&#xf3;n sist&#xe9;mica son indicadores de pron&#xf3;sticos &#xfa;tiles para el c&#xe1;ncer colorrectal metast&#xe1;sico. Sin embargo, la influencia de los genotipos KRAS en estos marcadores en pacientes con c&#xe1;ncer colorrectal metast&#xe1;sico no est&#xe1; clara.OBJETIVO:Evaluamos las asociaciones entre los sistemas de evaluaci&#xf3;n de la inflamaci&#xf3;n sist&#xe9;mica previa al tratamiento y los resultados seg&#xfa;n los genotipos K-ras en pacientes con c&#xe1;ncer colorrectal metast&#xe1;sico.AJUSTE:Este estudio se realiz&#xf3; en un hospital universitario.DISE&#xd1;O:Este fue un estudio retrospectivo.PACIENTES:Un total de 272 pacientes (K-ras wildtype [K-raswt]:mutant [K-rasMut] = 169:103) que recibieron quimioterapia sist&#xe9;mica de primera l&#xed;nea para el c&#xe1;ncer colorrectal metast&#xe1;sico.PRINCIPALES MEDIDAS DE RESULTADO:Calculamos retrospectivamente 8 &#xed;ndices de inflamaci&#xf3;n sist&#xe9;mica: proporci&#xf3;n de neutr&#xf3;filos/linfocitos, proporci&#xf3;n de plaquetas/linfocitos, proporci&#xf3;n de linfocitos/monocitos, &#xed;ndice nutricional pron&#xf3;stico, puntuaci&#xf3;n de pron&#xf3;stico de Glasgow, puntuaci&#xf3;n de pron&#xf3;stico de N&#xe1;poles, puntuaci&#xf3;n de inflamaci&#xf3;n sist&#xe9;mica e &#xed;ndice de inmunoinflamaci&#xf3;n sist&#xe9;mica. Los pacientes se clasificaron en grupos altos o bajos para cada &#xed;ndice. La relevancia pron&#xf3;stica de estos &#xed;ndices para la supervivencia global se evalu&#xf3; seg&#xfa;n el genotipo K-ras.RESULTADOS:Los an&#xe1;lisis de supervivencia de Kaplan-Meier mostraron que la mediana de la supervivencia general difer&#xed;a significativamente entre los grupos alto y bajo para todos los &#xed;ndices en el grupo K-raswt pero no en el grupo K-rasMut, excepto para la puntuaci&#xf3;n de pron&#xf3;stico de Glasgow y la proporci&#xf3;n de linfocitos/monocitos. Los an&#xe1;lisis de regresi&#xf3;n multivariable de Cox identificaron todos los &#xed;ndices como factores pron&#xf3;sticos independientes. En el grupo K-raswt, todos los &#xed;ndices, excepto el cociente plaquetas/linfocitos, tuvieron fuertes efectos pron&#xf3;sticos, pero no en el grupo K-rasMut. Las pruebas de interacci&#xf3;n indicaron que el genotipo K-ras influy&#xf3; significativamente en los impactos pron&#xf3;sticos de la proporci&#xf3;n de neutr&#xf3;filos/linfocitos (p = 0,042), el &#xed;ndice nutricional pron&#xf3;stico (p = 0,048), la puntuaci&#xf3;n pron&#xf3;stica de N&#xe1;poles (p &lt; 0,001) y el &#xed;ndice de inflamaci&#xf3;n inmunol&#xf3;gica sist&#xe9;mica (p = 0,004).LIMITACI&#xd3;N:Una limitaci&#xf3;n importante de este estudio es la falta de validaci&#xf3;n externa.CONCLUSI&#xd3;NES:La importancia pron&#xf3;stica de los &#xed;ndices de inflamaci&#xf3;n sist&#xe9;mica es m&#xe1;s &#xfa;til en pacientes con c&#xe1;ncer colorrectal metast&#xe1;sico K-raswt. Consulte Video Resumen en http://links.lww.com/DCR/B921 . (Traducci&#xf3;n-Dr. Yolanda Colorado ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiyama</LastName><ForeName>Takahiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Cancer Biology, International Research Centre for Medical Sciences, Kumamoto University, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Rikako</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawayama</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Katsuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Naoya</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Translational Research and Advanced Treatment Against Gastrointestinal Cancer, Kumamoto University, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baba</LastName><ForeName>Hideo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D016283">Proto-Oncogene Proteins p21(ras)</NameOfSubstance></Chemical><Chemical><RegistryNumber>003N66TS6T</RegistryNumber><NameOfSubstance UI="C031967">rasagiline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016283" MajorTopicYN="N">Proto-Oncogene Proteins p21(ras)</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="Y">Colonic Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006785" MajorTopicYN="N">Hospitals, University</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35195557</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002392</ArticleId><ArticleId IdType="pii">00003453-202308000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646&#x2013;674.</Citation></Reference><Reference><Citation>Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493&#x2013;e503.</Citation></Reference><Reference><Citation>Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436&#x2013;444.</Citation></Reference><Reference><Citation>Yang J, Guo X, Wang M, Ma X, Ye X, Lin P. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS. Sci Rep. 2017;7:17166.</Citation></Reference><Reference><Citation>Wu Q, Hu T, Zheng E, Deng X, Wang Z. Prognostic role of the lymphocyte-to-monocyte ratio in colorectal cancer: an up-to-date meta-analysis. Medicine (Baltimore). 2017;96:e7051.</Citation></Reference><Reference><Citation>Lu C, Gao P, Yang Y, et al. Prognostic evaluation of platelet to lymphocyte ratio in patients with colorectal cancer. Oncotarget. 2017;8:86287&#x2013;86295.</Citation></Reference><Reference><Citation>Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23:6261&#x2013;6272.</Citation></Reference><Reference><Citation>Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104:1288&#x2013;1295.</Citation></Reference><Reference><Citation>Lin GN, Liu PP, Liu DY, Peng JW, Xiao JJ, Xia ZJ. Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy. Chin J Cancer. 2016;35:5.</Citation></Reference><Reference><Citation>Kim I-H, Lee JE, Yang JH, Jeong JW, Ro S, Lee MA. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response. Asia Pac J Clin Oncol. 2018;14:239&#x2013;248.</Citation></Reference><Reference><Citation>Han CB, Li F, Ma JT, Zou HW. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest. 2012;30:741&#x2013;747.</Citation></Reference><Reference><Citation>Modest DP, Ricard I, Heinemann V, et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol. 2016;27:1746&#x2013;1753.</Citation></Reference><Reference><Citation>de Reyni&#xe8;s A, Boige V, Milano G, Faivre J, Laurent-Puig P. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol. 2008;26:2228&#x2013;2230.</Citation></Reference><Reference><Citation>Yu Z, Yu H, Zou Q, et al. Nomograms for prediction of molecular phenotypes in colorectal cancer. Onco Targets Ther. 2020;13:309&#x2013;321.</Citation></Reference><Reference><Citation>Correale P, Botta C, Staropoli N, et al. Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine. Oncotarget. 2018;9:20539&#x2013;20554.</Citation></Reference><Reference><Citation>McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol. 2005;2:416&#x2013;422.</Citation></Reference><Reference><Citation>Malietzis G, Giacometti M, Askari A, et al. A preoperative neutrophil to lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery. Ann Surg. 2014;260:287&#x2013;292.</Citation></Reference><Reference><Citation>Passardi A, Scarpi E, Cavanna L, et al. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget. 2016;7:33210&#x2013;33219.</Citation></Reference><Reference><Citation>Song A, Eo W, Lee S. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients. World J Gastroenterol. 2015;21:12410&#x2013;12420.</Citation></Reference><Reference><Citation>Tokunaga R, Sakamoto Y, Nakagawa S, et al. Comparison of systemic inflammatory and nutritional scores in colorectal cancer patients who underwent potentially curative resection. Int J Clin Oncol. 2017;22:740&#x2013;748.</Citation></Reference><Reference><Citation>Leitch EF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97:1266&#x2013;1270.</Citation></Reference><Reference><Citation>Gemenetzis G, Bagante F, Griffin JF, et al. Neutrophil-to-lymphocyte ratio is a predictive marker for invasive malignancy in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2017;266:339&#x2013;345.</Citation></Reference><Reference><Citation>Al Murri AM, Wilson C, Lannigan A, et al. Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br J Cancer. 2007;96:891&#x2013;895.</Citation></Reference><Reference><Citation>Nemoto T, Endo S, Isohata N, et al. Change in the neutrophil-to-lymphocyte ratio during chemotherapy may predict prognosis in patients with advanced or metastatic colorectal cancer. Mol Clin Oncol. 2021;14:107.</Citation></Reference><Reference><Citation>Shibutani M, Maeda K, Nagahara H, et al. The prognostic value of the systemic inflammatory score in patients with unresectable metastatic colorectal cancer. Oncol Lett. 2018;16:666&#x2013;672.</Citation></Reference><Reference><Citation>Huang Y, Li W, Quan Q, Zhang B, Yang Q. Glasgow prognostic score as a predictor of bevacizumab efficacy in the first-line treatment with metastatic colorectal cancer. J Cancer. 2019;10:6858&#x2013;6864.</Citation></Reference><Reference><Citation>Agalioti T, Giannou AD, Krontira AC, et al. Mutant KRAS promotes malignant pleural effusion formation. Nat Commun. 2017;8:15205.</Citation></Reference><Reference><Citation>Sunaga N, Imai H, Shimizu K, et al. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer. 2012;130:1733&#x2013;1744.</Citation></Reference><Reference><Citation>Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697&#x2013;4705.</Citation></Reference><Reference><Citation>Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18:6531&#x2013;6541.</Citation></Reference><Reference><Citation>Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466&#x2013;474.</Citation></Reference><Reference><Citation>Kimura H, Caturegli P, Takahashi M, Suzuki K. New insights into the function of the immunoproteasome in immune and nonimmune cells. J Immunol Res. 2015;2015:541984.</Citation></Reference><Reference><Citation>Gandhi AK, Shi T, Li M, et al. Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. PLoS One. 2013;8:e80437.</Citation></Reference><Reference><Citation>Kitayama J, Yasuda K, Kawai K, Sunami E, Nagawa H. Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer. 2011;11:64.</Citation></Reference><Reference><Citation>Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3:194&#x2013;201.</Citation></Reference><Reference><Citation>Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713&#x2013;1729.</Citation></Reference><Reference><Citation>Suzuki S, Akiyoshi T, Oba K, et al. Comprehensive comparative analysis of prognostic value of systemic inflammatory biomarkers for patients with stage II/III colon cancer. Ann Surg Oncol. 2020;27:844&#x2013;852.</Citation></Reference><Reference><Citation>Passardi A, Scarpi E, Tamberi S, et al. Impact of pre-treatment lactate dehydrogenase levels on prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. PLoS One. 2015;10:e0134732.</Citation></Reference><Reference><Citation>Yu SL, Xu LT, Qi Q, et al. Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy. Sci Rep. 2017;7:45194.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34623347</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Lymphocyte-to-C-Reactive Protein Ratio Is the Most Sensitive Inflammation-Based Prognostic Score in Patients With Unresectable Metastatic Colorectal Cancer.</ArticleTitle><Pagination><StartPage>1331</StartPage><EndPage>1341</EndPage><MedlinePgn>1331-1341</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002059</ELocationID><Abstract><AbstractText Label="BACKGROUND">Systemic inflammation contributes to the progression of malignancies. The preoperative lymphocyte-to-C-reactive protein ratio has recently been shown to predict survival of patients with colorectal cancer who undergo surgery, but its prognostic value remains unclear in patients with unresectable metastatic colorectal cancer.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to examine the prognostic values of inflammation-based prognostic scores in patients with metastatic colorectal cancer, focusing on the lymphocyte-to-C-reactive protein ratio.</AbstractText><AbstractText Label="DESIGN">This is a retrospective study from a prospectively collected database.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a high-volume multidisciplinary tertiary cancer center in Japan.</AbstractText><AbstractText Label="PATIENTS">The subjects were 756 consecutive patients with unresectable metastatic colorectal cancer who received systemic chemotherapy from 2000 to 2015. The prognostic value of the lymphocyte-to-C-reactive protein ratio was evaluated by univariable and multivariable analyses. Time-dependent receiver operating characteristics curve analysis was conducted to compare the prognostic impact of the lymphocyte-to-C-reactive protein ratio with the impact of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, or the modified Glasgow Prognostic Score.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcomes measured were the correlations of prognostic scores with overall survival.</AbstractText><AbstractText Label="RESULTS">Median survival times of patients with high, intermediate, and low lymphocyte-to-C-reactive protein ratios were 29.4, 19.3, and 13.1 months (p &lt; 0.001). In all subgroups according to key prognostic factors (performance status, use of targeted agents, pretreatment CEA levels, tumor sidedness, M category, and primary tumor resection), patient prognosis could be clearly stratified into 3 groups by the lymphocyte-to-C-reactive protein ratio. Multivariable analysis revealed that decreased lymphocyte-to-C-reactive protein ratio was independently associated with reduced survival (low vs high: HR 1.96, p &lt; 0.001; intermediate vs high: HR 1.44, p &lt; 0.001). The time-dependent receiver operating characteristics curve analysis revealed that the lymphocyte-to-C-reactive protein ratio was the most sensitive predictor of survival among all inflammation-based prognostic scores on a continuous basis.</AbstractText><AbstractText Label="LIMITATIONS">This study was retrospective in nature.</AbstractText><AbstractText Label="CONCLUSIONS">The lymphocyte-to-C-reactive protein ratio is a useful prognostic biomarker for unresectable metastatic colorectal cancer and could contribute to accurate prognostication and therapeutic decision making. See Video Abstract at http://links.lww.com/DCR/B600.</AbstractText><AbstractText Label="RELACIN ENTRE LINFOCITOS Y PROTENA C ES EL SCORE PRONOSTICO INFLAMATORIO MAS SENSIBLE EN PACIENTES CON CNCER COLORRECTAL METASTSICO IRRESECABLE">ANTECEDENTES:La inflamaci&#xf3;n sist&#xe9;mica contribuye en la progresi&#xf3;n de neoplasias malignas. Recientemente se ha demostrado que la proporci&#xf3;n preoperatoria de linfocitos -prote&#xed;na C reactiva predice la supervivencia de los pacientes con c&#xe1;ncer colorrectal que se sometieron a cirug&#xed;a, pero su valor pron&#xf3;stico sigue sin estar claro en pacientes con c&#xe1;ncer colorrectal metast&#xe1;sico irresecable.OBJETIVO:Evaluar el valor pronostico de los scores inflamtorios centrandose en linfocito- proteina c reactiva en pacientes con c&#xe1;ncer colorrectal metast&#xe1;sico.DISE&#xd1;O:Estudio retrospective evaluando una base de datos.AJUSTE:Este estudio se llev&#xf3; a cabo en un centro oncol&#xf3;gico terciario multidisciplinario de gran volumen en Jap&#xf3;n.PACIENTES:Se incluyeron 756 pacientes consecutivos todos con c&#xe1;ncer colorrectal metast&#xe1;sico irresecable que recibieron quimioterapia sist&#xe9;mica de 2000 a 2015. El valor pron&#xf3;stico de la prote&#xed;na C reactiva se evalu&#xf3; mediante an&#xe1;lisis univariables y multivariables. Se realiz&#xf3; an&#xe1;lisis de la curva de caracter&#xed;sticas operativas del receptor dependiente del tiempo para comparar el impacto pron&#xf3;stico de la prote&#xed;na linfocito-C-reactiva con el de la proporci&#xf3;n de neutr&#xf3;filos a linfocitos, la proporci&#xf3;n de plaquetas a linfocitos, la proporci&#xf3;n de linfocitos a monocitos o la proporci&#xf3;n de puntuaci&#xf3;n pron&#xf3;stica segun escala de Glasgow modificada.PRINCIPALES MEDIDAS DE RESULTADO:Correlacion de las puntuaciones pron&#xf3;sticas con la supervivencia global.RESULTADOS:La mediana de supervivencia de los pacientes con niveles altos, intermedios y bajos de prote&#xed;na C reactiva de linfocitos fue de 29,4, 19,3 y 13,1 meses, respectivamente (p &lt;0,001). En todos los subgrupos de acuerdo con los factores pron&#xf3;sticos clave (estado funcional, uso de agentes dirigidos, niveles de ant&#xed;geno carcinoembrionario antes del tratamiento, lado del tumor, categor&#xed;a M y resecci&#xf3;n del tumor primario), el pron&#xf3;stico del paciente podr&#xed;a estratificarse claramente en tres grupos por linfocito a C- prote&#xed;na reactiva. El an&#xe1;lisis multivariable revel&#xf3; que la disminuci&#xf3;n de linfocitos a prote&#xed;na C reactiva se asoci&#xf3; de forma independiente con una supervivencia reducida (baja frente a alta: cociente de riesgo 1,96, p &lt;0,001; intermedio frente a alto: cociente de riesgo 1,44, p &lt;0,001). El an&#xe1;lisis de la curva de caracter&#xed;sticas operativas del receptor dependiente del tiempo revel&#xf3; que de linfocito a prote&#xed;na C reactiva era el predictor de supervivencia m&#xe1;s sensible entre todas las puntuaciones de pron&#xf3;stico basadas en inflamaci&#xf3;n de forma continua.LIMITACIONES:Este estudio fue de naturaleza retrospectiva.CONCLUSIONES:La prote&#xed;na C reactiva de linfocitos a C es un biomarcador pron&#xf3;stico &#xfa;til para el c&#xe1;ncer colorrectal metast&#xe1;sico irresecable y podr&#xed;a contribuir a un pron&#xf3;stico preciso y a la toma de decisiones terap&#xe9;uticas. Consulte Video Resumen en http://links.lww.com/DCR/B600.</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shida</LastName><ForeName>Dai</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Frontier Surgery, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boku</LastName><ForeName>Narikazu</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Takefumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanabe</LastName><ForeName>Taro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Frontier Surgery, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takamizawa</LastName><ForeName>Yasuyuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takashima</LastName><ForeName>Atsuo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanemitsu</LastName><ForeName>Yukihide</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018655" MajorTopicYN="Y">Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>8</Day><Hour>12</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34623347</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002059</ArticleId><ArticleId IdType="pii">00003453-202111000-00007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646&#x2013;674.</Citation></Reference><Reference><Citation>Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493&#x2013;e503.</Citation></Reference><Reference><Citation>Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436&#x2013;444.</Citation></Reference><Reference><Citation>Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. Ann Surg. 2020;272:342&#x2013;351.</Citation></Reference><Reference><Citation>Dolan RD, Lim J, McSorley ST, Horgan PG, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis. Sci Rep. 2017;7:16717.</Citation></Reference><Reference><Citation>Dolan RD, McSorley ST, Horgan PG, Laird B, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;116:134&#x2013;146.</Citation></Reference><Reference><Citation>Rossi S, Basso M, Strippoli A, et al. Are markers of systemic inflammation good prognostic indicators in colorectal cancer? Clin Colorectal Cancer. 2017;16:264&#x2013;274.</Citation></Reference><Reference><Citation>Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer. Clin Nutr. 2020;39:1209&#x2013;1217.</Citation></Reference><Reference><Citation>Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med Res Methodol. 2017;17:53.</Citation></Reference><Reference><Citation>Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 2017.8th ed. New York: John Wiley &amp; Sons Ltd.;</Citation></Reference><Reference><Citation>Shida D, Tanabe T, Boku N, et al. Prognostic value of primary tumor sidedness for unresectable stage IV colorectal cancer: a retrospective study. Ann Surg Oncol. 2019;26:1358&#x2013;1365.</Citation></Reference><Reference><Citation>Shida D, Tsukamoto S, Ochiai H, Kanemitsu Y. Long-term outcomes after R0 resection of synchronous peritoneal metastasis from colorectal cancer without cytoreductive surgery or hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2018;25:173&#x2013;178.</Citation></Reference><Reference><Citation>Shida D, Ahiko Y, Tanabe T, et al. Shorter survival in adolescent and young adult patients, compared to adult patients, with stage IV colorectal cancer in Japan. BMC Cancer. 2018;18:334.</Citation></Reference><Reference><Citation>Shida D, Yoshida T, Tanabe T, Tsukamoto S, Ochiai H, Kanemitsu Y. Prognostic impact of R0 resection and targeted therapy for colorectal cancer with synchronous peritoneal metastasis. Ann Surg Oncol. 2018;25:1646&#x2013;1653.</Citation></Reference><Reference><Citation>Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104:1288&#x2013;1295.</Citation></Reference><Reference><Citation>Tan D, Fu Y, Su Q, Wang H. Prognostic role of platelet-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95:e3837.</Citation></Reference><Reference><Citation>Stotz M, Pichler M, Absenger G, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110:435&#x2013;440.</Citation></Reference><Reference><Citation>Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC. Colorectal cancer, systemic inflammation, and outcome: staging the tumor and staging the host. Ann Surg. 2016;263:326&#x2013;336.</Citation></Reference><Reference><Citation>Shida D, Hamaguchi T, Ochiai H, et al. Prognostic impact of palliative primary tumor resection for unresectable stage 4 colorectal cancer: using a propensity score analysis. Ann Surg Oncol. 2016;23:3602&#x2013;3608.</Citation></Reference><Reference><Citation>Sjoquist KM, Renfro LA, Simes RJ, et al.; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD). Personalizing survival predictions in advanced colorectal cancer: the ARCAD Nomogram Project. J Natl Cancer Inst. 2018;110:638&#x2013;648.</Citation></Reference><Reference><Citation>Suzuki Y, Okabayashi K, Hasegawa H, et al. Comparison of preoperative inflammation-based prognostic scores in patients with colorectal cancer. Ann Surg. 2018;267:527&#x2013;531.</Citation></Reference><Reference><Citation>Park JH, McMillan DC, Horgan PG, Roxburgh CS. The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer. Cancer Treat Rev. 2014;40:68&#x2013;77.</Citation></Reference><Reference><Citation>Caglayan K, Oner I, Gunerhan Y, Ata P, Koksal N, Ozkara S. The impact of preoperative immunonutrition and other nutritionyears from diagnosis models on tumor infiltrative lymphocytes in colorectal cancer patients. Am J Surg. 2012;204:416&#x2013;421.</Citation></Reference><Reference><Citation>Okugawa Y, Shirai Y, Toiyama Y, et al. Clinical burden of modified Glasgow Prognostic Scale in colorectal cancer. Anticancer Res. 2018;38:1599&#x2013;1610.</Citation></Reference><Reference><Citation>Xu J, Sun X, Xin Q, et al. Effect of immunonutrition on colorectal cancer patients undergoing surgery: a meta-analysis. Int J Colorectal Dis. 2018;33:273&#x2013;283.</Citation></Reference><Reference><Citation>Adiamah A, Sko&#x159;epa P, Weimann A, Lobo DN. The impact of preoperative immune modulating nutrition on outcomes in patients undergoing surgery for gastrointestinal cancer: a systematic review and meta-analysis. Ann Surg. 2019;270:247&#x2013;256.</Citation></Reference><Reference><Citation>Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 2010;7:153&#x2013;162.</Citation></Reference><Reference><Citation>Azab B, Camacho-Rivera M, Taioli E. Average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of United States subjects. PLoS One. 2014;9:e112361.</Citation></Reference><Reference><Citation>Park JH, Ishizuka M, McSorley ST, et al. Staging the tumor and staging the host: a two centre, two country comparison of systemic inflammatory responses of patients undergoing resection of primary operable colorectal cancer. Am J Surg. 2018;216:458&#x2013;464.</Citation></Reference><Reference><Citation>Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y, Kusunoki M. Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med. 2011;2:95&#x2013;101.</Citation></Reference><Reference><Citation>Inoue Y, Iwata T, Okugawa Y, et al. Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer. Oncology. 2013;84:100&#x2013;107.</Citation></Reference><Reference><Citation>Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489&#x2013;495.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34192711</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>A US Rectal Cancer Consortium Study of Inferior Mesenteric Artery Versus Superior Rectal Artery Ligation: How High Do We Need to Go?</ArticleTitle><Pagination><StartPage>1198</StartPage><EndPage>1211</EndPage><MedlinePgn>1198-1211</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002052</ELocationID><Abstract><AbstractText Label="BACKGROUND">The optimal level of pedicle ligation during proctectomy for rectal cancer, either at the origin of the inferior mesenteric artery or the superior rectal artery, is still debated.</AbstractText><AbstractText Label="OBJECTIVE">The objective was to determine whether superior rectal artery ligation portends equivalent technical or oncologic outcomes.</AbstractText><AbstractText Label="DESIGN">This was a retrospective analysis of a rectal cancer database (2007-2017).</AbstractText><AbstractText Label="SETTINGS">The study was conducted at 6 tertiary referral centers in the United States (Emory University, University of Michigan, University of Pittsburgh Medical Center, The Ohio State University Wexner Medical Center, Vanderbilt University Medical Center, and Washington University School of Medicine in St. Louis).</AbstractText><AbstractText Label="PATIENTS">Patients with primary, nonmetastatic rectal cancer who underwent low anterior resection or abdominoperineal resection were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Anastomotic leak, lymph node harvest, locoregional recurrence-free survival, recurrence-free survival, and overall survival were measured.</AbstractText><AbstractText Label="RESULTS">Of 877 patients, 86% (n = 755) received an inferior mesenteric artery ligation, whereas 14% (n = 122) received a superior rectal artery ligation. A total of 12%, 33%, 24%, and 31% were pathologic stage 0, I, II, and III. Median follow-up was 31 months. Superior rectal artery ligation was associated with a similar anastomotic leak rate compared with inferior mesenteric artery ligation (9% vs 8%; p = 1.0). The median number of lymph nodes removed was identical (15 vs 15; p = 0.38). On multivariable analysis accounting for relevant clinicopathologic factors, superior rectal artery ligation was not associated with increased anastomotic leak rate, worse lymph node harvest, or worse locoregional recurrence-free survival, recurrence-free survival, or overall survival (all p values &gt;0.1).</AbstractText><AbstractText Label="LIMITATIONS">This was a retrospective design.</AbstractText><AbstractText Label="CONCLUSIONS">Compared with inferior mesenteric artery ligation, superior rectal artery ligation is not associated with either worse technical or oncologic outcomes. Given the potential risks of inadequate blood flow to the proximal limb of the anastomosis and autonomic nerve injury, we advocate for increased use of superior rectal artery ligation. See Video Abstract at http://links.lww.com/DCR/B646.</AbstractText><AbstractText Label="ESTUDIO DEL CONSORCIO DE CNCER DE RECTO DE ESTADOS UNIDOS DE LIGADURA BAJA DE LA ARTERIA MESENTRICA INFERIOR CONTRA LIGADURA ALTA DE LA ARTERIA MESENTRICA INFERIOR QU TAN ALTO DEBEMOS EXTENDERNOS">ANTECEDENTES:el nivel &#xf3;ptimo de la ligadura del ped&#xed;culo en la proctectom&#xed;a para el c&#xe1;ncer de recto, ya sea en el origen de la arteria mesent&#xe9;rica inferior o en la arteria rectal superior a&#xfa;n no esta definido.OBJETIVO:El objetivo era determinar si la ligadura de la arteria rectal superior pronostica resultados t&#xe9;cnicos u oncol&#xf3;gicos similares.DISE&#xd1;O:An&#xe1;lisis retrospectivo de una base de datos de c&#xe1;ncer de recto (2007-2017).ESCENARIO:el estudio se realiz&#xf3; en seis centros de referencia de tercer nivel en los Estados Unidos (Universidad de Emory, Universidad de Michigan, Centro m&#xe9;dico de la Universidad de Pittsburgh, Centro m&#xe9;dico Wexner de la Universidad Estatal de Ohio, Centro m&#xe9;dico de la Universidad de Vanderbilt y Escuela de Medicina de la Universidad de Washington en St. Louis).PACIENTES:Se incluyeron pacientes con c&#xe1;ncer de recto primario no metast&#xe1;sico que se sometieron a resecci&#xf3;n anterior baja o resecci&#xf3;n abdominoperineal.PRINCIPALES VARIABLES ANALIZADAS:Se midi&#xf3; la fuga anastom&#xf3;tica, los ganglios linf&#xe1;ticos recuperados, la sobrevida sin recidiva locorregional, la sobrevida sin recidiva y la sobrevida global.RESULTADOS:De 877 pacientes, en el 86% (n = 755) se realiz&#xf3; una ligadura de la arteria mesent&#xe9;rica inferior, y en el 14% (n = 122) se realiz&#xf3; una ligadura de la arteria rectal superior. El 12%, 33%, 24% y 31% estaban en estadio patol&#xf3;gico 0, I, II y III respectivamente. La mediana de seguimiento fue de 31 meses. La ligadura de la arteria rectal superior se asoci&#xf3; con una tasa de fuga anastom&#xf3;tica similar a la ligadura de la arteria mesent&#xe9;rica inferior (9 vs 8%, p = 1,0). La mediana del n&#xfa;mero de ganglios linf&#xe1;ticos extirpados fue id&#xe9;ntica (15 contra 15, p = 0,38). En el an&#xe1;lisis multivariado que tiene en cuenta los factores cl&#xed;nico-patol&#xf3;gicos relevantes, la ligadura de la arteria rectal superior no se asoci&#xf3; con una mayor tasa de fuga anastom&#xf3;tica, una peor cosecha de ganglios linf&#xe1;ticos o una peor sobrevida libre de recurrencia locorregional, sobrevida libre de recurrencia o sobrevida global (todos p&gt; 0,1).LIMITACIONES:Dise&#xf1;o retrospectivo.CONCLUSIONES:En comparaci&#xf3;n con la ligadura de la arteria mesent&#xe9;rica inferior, la ligadura de la arteria rectal superior no se asocia a peores resultados t&#xe9;cnicos ni oncol&#xf3;gicos. Debido a los riesgos potenciales de un flujo sangu&#xed;neo inadecuado del mu&#xf1;on proximal de la anastomosis y la lesi&#xf3;n de los nervios auton&#xf3;micos, proponemos una mayor realizaci&#xf3;n de la ligadura de la arteria rectal superior. Consulte Video Resumen en http://links.lww.com/DCR/B646.</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Turgeon</LastName><ForeName>Michael K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamboa</LastName><ForeName>Adriana C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regenbogen</LastName><ForeName>Scott E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holder-Murray</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdel-Misih</LastName><ForeName>Sherif R Z</ForeName><Initials>SRZ</Initials><AffiliationInfo><Affiliation>Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawkins</LastName><ForeName>Alexander T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Section of Colon and Rectal Surgery, Division of General Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silviera</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Section of Colon &amp; Rectal Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maithel</LastName><ForeName>Shishir K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balch</LastName><ForeName>Glen C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TL1 TR002382</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002378</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2021 Oct 1;64(10):1157-1158. doi: 10.1097/DCR.0000000000002195.</RefSource><PMID Version="1">34192712</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057868" MajorTopicYN="N">Anastomotic Leak</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008026" MajorTopicYN="N">Ligation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017537" MajorTopicYN="N">Mesenteric Artery, Inferior</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012007" MajorTopicYN="N">Rectum</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012958" MajorTopicYN="N">Societies, Scientific</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText Label="ANTECEDENTES:">el nivel &#xf3;ptimo de la ligadura del ped&#xed;culo en la proctectom&#xed;a para el c&#xe1;ncer de recto, ya sea en el origen de la arteria mesent&#xe9;rica inferior o en la arteria rectal superior a&#xfa;n no esta definido.</AbstractText><AbstractText Label="OBJETIVO:">El objetivo era determinar si la ligadura de la arteria rectal superior pronostica resultados t&#xe9;cnicos u oncol&#xf3;gicos similares.</AbstractText><AbstractText Label="DISE&#xd1;O:">An&#xe1;lisis retrospectivo de una base de datos de c&#xe1;ncer de recto (2007-2017).</AbstractText><AbstractText Label="ESCENARIO:">el estudio se realiz&#xf3; en seis centros de referencia de tercer nivel en los Estados Unidos (Universidad de Emory, Universidad de Michigan, Centro m&#xe9;dico de la Universidad de Pittsburgh, Centro m&#xe9;dico Wexner de la Universidad Estatal de Ohio, Centro m&#xe9;dico de la Universidad de Vanderbilt y Escuela de Medicina de la Universidad de Washington en St. Louis).</AbstractText><AbstractText Label="PACIENTES:">Se incluyeron pacientes con c&#xe1;ncer de recto primario no metast&#xe1;sico que se sometieron a resecci&#xf3;n anterior baja o resecci&#xf3;n abdominoperineal.</AbstractText><AbstractText Label="PRINCIPALES VARIABLES ANALIZADAS:">Se midi&#xf3; la fuga anastom&#xf3;tica, los ganglios linf&#xe1;ticos recuperados, la sobrevida sin recidiva locorregional, la sobrevida sin recidiva y la sobrevida global.</AbstractText><AbstractText Label="RESULTADOS:">De 877 pacientes, en el 86% (<i>n</i> = 755) se realiz&#xf3; una ligadura de la arteria mesent&#xe9;rica inferior, y en el 14% (<i>n</i> = 122) se realiz&#xf3; una ligadura de la arteria rectal superior. El 12%, 33%, 24% y 31% estaban en estadio patol&#xf3;gico 0, I, II y III respectivamente. La mediana de seguimiento fue de 31 meses. La ligadura de la arteria rectal superior se asoci&#xf3; con una tasa de fuga anastom&#xf3;tica similar a la ligadura de la arteria mesent&#xe9;rica inferior (9 vs 8%, <i>p</i> = 1,0). La mediana del n&#xfa;mero de ganglios linf&#xe1;ticos extirpados fue id&#xe9;ntica (15 contra 15, <i>p</i> = 0,38). En el an&#xe1;lisis multivariado que tiene en cuenta los factores cl&#xed;nico-patol&#xf3;gicos relevantes, la ligadura de la arteria rectal superior no se asoci&#xf3; con una mayor tasa de fuga anastom&#xf3;tica, una peor cosecha de ganglios linf&#xe1;ticos o una peor sobrevida libre de recurrencia locorregional, sobrevida libre de recurrencia o sobrevida global (todos <i>p</i>&gt; 0,1).</AbstractText><AbstractText Label="LIMITACIONES:">Dise&#xf1;o retrospectivo.</AbstractText><AbstractText Label="CONCLUSIONES:">En comparaci&#xf3;n con la ligadura de la arteria mesent&#xe9;rica inferior, la ligadura de la arteria rectal superior no se asocia a peores resultados t&#xe9;cnicos ni oncol&#xf3;gicos. Debido a los riesgos potenciales de un flujo sangu&#xed;neo inadecuado del mu&#xf1;on proximal de la anastomosis y la lesi&#xf3;n de los nervios auton&#xf3;micos, proponemos una mayor realizaci&#xf3;n de la ligadura de la arteria rectal superior. Consulte <b>Video Resumen</b> en http://links.lww.com/DCR/B646. <i>(Traducci&#xf3;n&#x2014;Dr Lisbeth Alarcon-Bernes)</i></AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>30</Day><Hour>20</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34192711</ArticleId><ArticleId IdType="mid">NIHMS1749955</ArticleId><ArticleId IdType="pmc">PMC8573719</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002052</ArticleId><ArticleId IdType="pii">00003453-202110000-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">32133645</ArticleId></ArticleIdList></Reference><Reference><Citation>Nano M, Dal Corso H, Ferronato M, Solej M, Hornung JP, Dei Poli M. Ligation of the inferior mesenteric artery in the surgery of rectal cancer: anatomical considerations. Dig Surg. 2004;21:123&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">15026607</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin CC, Yeh CY, Tang R, Changchien CR, Huang WS, Wang JY. The oncologic benefit of high ligation of the inferior mesenteric artery in the surgical treatment of rectal or sigmoid colon cancer. Int J Colorectal Dis. 2008;23:783&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">18438677</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JD, Eskicioglu C, Weiser MR, Feingold DL, Steele SR. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of colon cancer. Dis Colon Rectum. 2017;60:999&#x2013;1017.</Citation><ArticleIdList><ArticleId IdType="pubmed">28891842</ArticleId></ArticleIdList></Reference><Reference><Citation>Vennix S, Pelzers L, Bouvy N, et al. Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database SystRev. 2014;(4):CD005200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10875406</ArticleId><ArticleId IdType="pubmed">24737031</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourley EJ, Gering SA. The meandering mesenteric artery: a historic review and surgical implications. Dis Colon Rectum. 2005;48:996&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">15933893</ArticleId></ArticleIdList></Reference><Reference><Citation>Warschkow R, Steffen T, Thierbach J, Bruckner T, Lange J, Tarantino I. Risk factors for anastomotic leakage after rectal cancer resection and reconstruction with colorectostomy: a retrospective study with bootstrap analysis. Ann Surg Oncol. 2011;18:2772&#x2013;2782.</Citation><ArticleIdList><ArticleId IdType="pubmed">21468782</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Gu J. Risk factors for symptomatic anastomotic leakage after low anterior resection for rectal cancer with 30 Gy/10 f/2 w preoperative radiotherapy. World J Surg. 2010;34:1080&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">20145926</ArticleId></ArticleIdList></Reference><Reference><Citation>Parthasarathy M, Greensmith M, Bowers D, Groot-Wassink T. Risk factors for anastomotic leakage after colorectal resection: a retrospective analysis of 17 518 patients. Colorectal Dis. 2017;19:288&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">27474844</ArticleId></ArticleIdList></Reference><Reference><Citation>Shogan BD, Carlisle EM, Alverdy JC, Umanskiy K. Do we really know why colorectal anastomoses leak? J Gastrointest Surg. 2013;17:1698&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pubmed">23690209</ArticleId></ArticleIdList></Reference><Reference><Citation>Milgrom SA, Goodman KA, Nash GM, et al. Neoadjuvant radiation therapy prior to total mesorectal excision for rectal cancer is not associated with postoperative complications using current techniques. Ann Surg Oncol. 2014;21:2295&#x2013;2302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632492</ArticleId><ArticleId IdType="pubmed">24604589</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden DM, Mora Pinzon MC, Francescatti AB, Saclarides TJ. Patient factors may predict anastomotic complications after rectal cancer surgery: anastomotic complications in rectal cancer. Ann Med Surg (Lond). 2015;4:11&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4323762</ArticleId><ArticleId IdType="pubmed">25685338</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruteg&#xe5;rd M, Hemmingsson O, Matthiessen P, Ruteg&#xe5;rd J. High tie in anterior resection for rectal cancer confers no increased risk of anastomotic leakage. Br J Surg. 2012;99:127&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">22038493</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii S, Ishibe A, Ota M, et al. Randomized clinical trial of high versus low inferior mesenteric artery ligation during anterior resection for rectal cancer. BJS Open. 2018;2:195&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6069351</ArticleId><ArticleId IdType="pubmed">30079388</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirocchi R, Trastulli S, Farinella E, et al. High tie versus low tie of the inferior mesenteric artery in colorectal cancer: a RCT is needed. Surg Oncol. 2012;21:e111&#x2013;e123.</Citation><ArticleIdList><ArticleId IdType="pubmed">22770982</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Wang G, He J, Zhang J, Xi J, Wang F. High tie versus low tie of the inferior mesenteric artery in colorectal cancer: a meta-analysis. Int J Surg. 2018;52:20&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">29432970</ArticleId></ArticleIdList></Reference><Reference><Citation>AlSuhaimi MA, Yang SY, Kang JH, AlSabilah JF, Hur H, Kim NK. Operative safety and oncologic outcomes in rectal cancer based on the level of inferior mesenteric artery ligation: a stratified analysis of a large Korean cohort. Ann Surg Treat Res. 2019;97:254&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6848010</ArticleId><ArticleId IdType="pubmed">31742210</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajibandeh S, Hajibandeh S, Maw A. Meta-analysis and trial sequential analysis of randomized controlled trials comparing high and low ligation of the inferior mesenteric artery in rectal cancer surgery. Dis Colon Rectum. 2020;63:988&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">32243350</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabriel E, Attwood K, Al-Sukhni E, Erwin D, Boland P, Nurkin S. Age-related rates of colorectal cancer and the factors associated with overall survival. J Gastrointest Oncol. 2018;9:96&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5848036</ArticleId><ArticleId IdType="pubmed">29564176</ArticleId></ArticleIdList></Reference><Reference><Citation>Boakye D, Jansen L, Schneider M, Chang-Claude J, Hoffmeister M, Brenner H. Personalizing the prediction of colorectal cancer prognosis by incorporating comorbidities and functional status into prognostic nomograms. Cancers (Basel). 2019;11:E1435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6826360</ArticleId><ArticleId IdType="pubmed">31561507</ArticleId></ArticleIdList></Reference><Reference><Citation>Titu LV, Tweedle E, Rooney PS. High tie of the inferior mesenteric artery in curative surgery for left colonic and rectal cancers: a systematic review. Dig Surg. 2008;25:148&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">18446037</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Zhang S, Huang J, et al. Accurate low ligation of inferior mesenteric artery and root lymph node dissection according to different vascular typing in laparoscopic radical resection of rectal cancer [in Chinese]. Zhonghua Wei Chang Wai KeZa Zhi. 2018;21:46&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">29354899</ArticleId></ArticleIdList></Reference><Reference><Citation>You X, Liu Q, Wu J, et al. High versus low ligation of inferior mesenteric artery during laparoscopic radical resection of rectal cancer: a retrospective cohort study. Medicine (Baltimore). 2020;99:e19437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7220455</ArticleId><ArticleId IdType="pubmed">32195939</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet S, Berger A, Hentati N, et al. High tie versus low tie vascular ligation of the inferior mesenteric artery in colorectal cancer surgery: impact on the gain in colon length and implications on the feasibility of anastomoses. Dis Colon Rectum. 2012;55:515&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">22513429</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Ma P, Zhang X, et al. Preservation versus non-preservation of left colic artery in colorectal cancer surgery: an updated systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e13720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380791</ArticleId><ArticleId IdType="pubmed">30702552</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J, Su G. High ligation of the inferior mesenteric artery during sigmoid colon and rectal cancer surgery increases the risk of anastomotic leakage: a meta-analysis. World J Surg Oncol. 2018;16:157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091013</ArticleId><ArticleId IdType="pubmed">30071856</ArticleId></ArticleIdList></Reference><Reference><Citation>Beppu N, Matsubara N, Noda M, et al. A&#x2019;high tieconfers an increased risk of anastomotic leakage for lower rectal cancer surgery in patients treated with preoperative radiotherapy. Surg Today. 2015;45:600&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">25208814</ArticleId></ArticleIdList></Reference><Reference><Citation>Aqar HI, Kuzu MA. Important points for protection of the autonomic nerves during total mesorectal excision. Dis Colon Rectum. 2012;55:907&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">22810478</ArticleId></ArticleIdList></Reference><Reference><Citation>Moszkowicz D, Alsaid B, Bessede T, et al. Where does pelvic nerve injury occur during rectal surgery for cancer? Colorectal Dis. 2011;13:1326&#x2013;1334.</Citation><ArticleIdList><ArticleId IdType="pubmed">20718836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kverneng Hultberg D, Afshar AA, Rutegard J, et al. Level of vascular tie and its effect on functional outcome 2 years after anterior resection for rectal cancer. Colorectal Dis. 2017;19:987&#x2013;995.</Citation><ArticleIdList><ArticleId IdType="pubmed">28544473</ArticleId></ArticleIdList></Reference><Reference><Citation>Mari GM, Crippa J, Cocozza E, et al. Low ligation of inferior mesenteric artery in laparoscopic anterior resection for rectal cancer reduces genitourinary dysfunction: results from a randomized controlled trial (HIGHLOW Trial). Ann Surg. 2019;269:1018&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">31082897</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33990498</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Decreased Tumoral Expression of Colon-Specific Water Channel Aquaporin 8 Is Associated With Reduced Overall Survival in Colon Adenocarcinoma.</ArticleTitle><Pagination><StartPage>1083</StartPage><EndPage>1095</EndPage><MedlinePgn>1083-1095</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002071</ELocationID><Abstract><AbstractText Label="BACKGROUND">Colon cancer survival is dependent on metastatic potential and treatment. Large RNA-sequencing data sets may assist in identifying colon cancer-specific biomarkers to improve patient outcomes.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to identify a highly specific biomarker for overall survival in colon adenocarcinoma by using an RNA-sequencing data set.</AbstractText><AbstractText Label="DESIGN">Raw RNA-sequencing and clinical data for patients with colon adenocarcinoma (n = 271) were downloaded from The Cancer Genome Atlas. A binomial regression model was used to calculate differential RNA expression between paired colon cancer and normal epithelium samples (n = 40). Highly differentially expressed RNAs were examined.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at the University of Louisville using data acquired by The Cancer Genome Atlas.</AbstractText><AbstractText Label="PATIENTS">Patients from US accredited cancer centers between 1998 and 2013 were analyzed.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome measures were recurrence-free and overall survival.</AbstractText><AbstractText Label="RESULTS">The median age was 66 years (147/271 men, 180/271 White patients). Thirty RNAs were differentially expressed in colon adenocarcinoma compared with paired normal epithelium, using a log-fold change cutoff of &#xb1;6. Using median expression as a cutoff, 4 RNAs were associated with worse overall survival: decreased ZG16 (log-rank = 0.023), aquaporin 8 (log-rank = 0.023), and SLC26A3 (log-rank = 0.098), and increased COL1A1 (log-rank = 0.105). On multivariable analysis, low aquaporin 8 expression (HR, 1.748; 95% CI, 1.016-3.008; p = 0.044) was a risk factor for worse overall survival. Our final aquaporin 8 model had an area under the curve of 0.85 for overall survival. On subgroup analysis, low aquaporin 8 was associated with worse overall survival in patients with high microsatellite instability and in patients with stage II disease. Low aquaporin 8 expression was associated with KRAS and BRAF mutations. Aquaporin 8 immunohistochemistry was optimized for clinical application.</AbstractText><AbstractText Label="LIMITATIONS">This was a retrospective study.</AbstractText><AbstractText Label="CONCLUSION">Aquaporin 8 is a water channel selectively expressed in normal colon tissue. Low aquaporin 8 expression is a risk factor for worse overall survival in patients who have colon cancer. Aquaporin 8 measurement may have a role as a colon-specific prognostic biomarker and help in patient risk stratification for increased surveillance. See Video Abstract at http://links.lww.com/DCR/B603.</AbstractText><AbstractText Label="LA DISMINUCIN DE LA EXPRESIN TUMORAL DE LA ACUAPORINA DEL CANAL DE AGUA ESPECFICO DEL COLON SE ASOCIA CON UNA REDUCCIN DE LA SUPERVIVENCIA GENERAL EN EL ADENOCARCINOMA DE COLON">ANTECEDENTES:La supervivencia del c&#xe1;ncer de colon depende del potencial metast&#xe1;sico y del tratamiento. Grandes conjuntos de datos de secuenciaci&#xf3;n de ARN pueden ayudar a identificar biomarcadores espec&#xed;ficos del c&#xe1;ncer de colon para mejorar los resultados de los pacientes.OBJETIVO:Identificar un biomarcador altamente espec&#xed;fico para la supervivencia general en el adenocarcinoma de colon utilizando un conjunto de datos de secuenciaci&#xf3;n de ARN.DISE&#xd1;O:La secuenciaci&#xf3;n de ARN sin procesar y los datos cl&#xed;nicos para pacientes con adenocarcinoma de colon (n = 271) se descargaron de The Cancer Genome Atlas. Se utiliz&#xf3; un modelo de regresi&#xf3;n binomial para calcular la expresi&#xf3;n diferencial de ARN entre muestras de c&#xe1;ncer de colon emparejadas y muestras de epitelio normal (n = 40). Se examinaron los ARN expresados de forma altamente diferencial.ENTORNO CLINICO:Este estudio se realiz&#xf3; en la Universidad de Louisville utilizando datos adquiridos por The Cancer Genome Atlas.PACIENTES:Se analizaron pacientes de centros oncol&#xf3;gicos acreditados en Estados Unidos entre 1998-2013.PRINCIPALES MEDIDAS DE VALORACION:Las principales medidas de valoraci&#xf3;n fueron la supervivencia general y libre de recurrencia.RESULTADOS:La mediana de edad fue de 66 a&#xf1;os (147/271 hombres, 180/271 cauc&#xe1;sicos). Treinta ARN se expresaron diferencialmente en el adenocarcinoma de colon en comparaci&#xf3;n con el epitelio normal emparejado, utilizando un l&#xed;mite de cambio logar&#xed;tmico de &#xb1; 6. Utilizando la expresi&#xf3;n mediana como punto de corte, cuatro ARN se asociaron con una peor supervivencia general: disminuci&#xf3;n de ZG16 (rango logar&#xed;tmico = 0,023), acuaporina8 (rango logar&#xed;tmico = 0,023) y SLC26A3 (rango logar&#xed;tmico = 0,098) y aumento de COL1A1 (log -rango = 0,105). En el an&#xe1;lisis multivariable, la baja expresi&#xf3;n de acuaporina8 (HR = 1,748, IC del 95%: 1,016-3,008, p = 0,044) fue un factor de riesgo para una peor supervivencia global. Nuestro modelo de aquaporin8 final tuvo un AUC de 0,85 para la supervivencia global. En el an&#xe1;lisis de subgrupos, la acuaporina8 baja se asoci&#xf3; con una peor supervivencia general en pacientes con MSI-H y en pacientes en estadio II. La baja expresi&#xf3;n de acuaporina8 se asoci&#xf3; con mutaciones de KRAS y BRAF. La inmunohistoqu&#xed;mica de aquaporina8 se optimiz&#xf3; para su aplicaci&#xf3;n cl&#xed;nica.LIMITACIONES:Este fue un estudio retrospectivo.CONCLUSI&#xd3;N:La acuaporina8 es un canal de agua expresado selectivamente en el tejido normal del colon. La baja expresi&#xf3;n de AQP8 es un factor de riesgo de peor supervivencia global en pacientes con c&#xe1;ncer de colon. La medici&#xf3;n de aquaporina8 puede tener un papel como un biomarcador de pron&#xf3;stico espec&#xed;fico del colon y ayudar en la estratificaci&#xf3;n del riesgo del paciente para una mayor vigilancia. Consulte Video Resumen en http://links.lww.com/DCR/B603.</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Price Institute of Surgical Research, Hiram C. Polk, Jr. MD, Department of Surgery, University of Louisville School of Medicine, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalbfleisch</LastName><ForeName>Theodore</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Veterinary Science, Gluck Equine Research Center, University of Kentucky, Lexington, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Sudhir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Agricultural Bioinformatics, ICAR-Indian Agricultural Statistics Research Institute, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Jianmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rai</LastName><ForeName>Shesh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petras</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Pathology, Northeast Ohio Medical University, Rootstown, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ronquillo</LastName><ForeName>Nemencio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polk</LastName><ForeName>Hiram C</ForeName><Initials>HC</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Price Institute of Surgical Research, Hiram C. Polk, Jr. MD, Department of Surgery, University of Louisville School of Medicine, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galandiuk</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Price Institute of Surgical Research, Hiram C. Polk, Jr. MD, Department of Surgery, University of Louisville School of Medicine, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020346">Aquaporins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C117307">KRAS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C108330">aquaporin 8</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C482119">BRAF protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D016283">Proto-Oncogene Proteins p21(ras)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020346" MajorTopicYN="N">Aquaporins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053842" MajorTopicYN="N">Microsatellite Instability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048493" MajorTopicYN="N">Proto-Oncogene Proteins B-raf</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016283" MajorTopicYN="N">Proto-Oncogene Proteins p21(ras)</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33990498</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002071</ArticleId><ArticleId IdType="pii">00003453-202109000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7&#x2013;30.</Citation></Reference><Reference><Citation>Osterman E, Glimelius B. Recurrence risk after up-to-date colon cancer staging, surgery, and pathology: analysis of the entire Swedish population. Dis Colon Rectum. 2018;61:1016&#x2013;1025.</Citation></Reference><Reference><Citation>Morris EJ, Forman D, Thomas JD, et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg. 2010;97:1110&#x2013;1118.</Citation></Reference><Reference><Citation>NCCN Clinical Practice Guidelines in Oncology- Colon Cancer. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf . Accessed April 30, 2020.</Citation></Reference><Reference><Citation>Weiser MR, Landmann RG, Kattan MW, et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol. 2008;26:380&#x2013;385.</Citation></Reference><Reference><Citation>Takagawa R, Fujii S, Ohta M, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008;15:3433&#x2013;3439.</Citation></Reference><Reference><Citation>Lee DW, Kim KJ, Han SW, et al. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. Ann Surg Oncol. 2015;22:187&#x2013;194.</Citation></Reference><Reference><Citation>Yoon HH, Tougeron D, Shi Q, et al.; Alliance for Clinical Trials in Oncology. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 2014;20:3033&#x2013;3043.</Citation></Reference><Reference><Citation>Sho S, Court CM, Winograd P, Russell MM, Tomlinson JS. A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer. J Surg Oncol. 2017;116:996&#x2013;1004.</Citation></Reference><Reference><Citation>Liu Y, Liu B, Jin G, et al. An integrated three-long non-coding RNA signature predicts prognosis in colorectal cancer patients. Front Oncol. 2019;9:1269.</Citation></Reference><Reference><Citation>Li S, Chen S, Wang B, Zhang L, Su Y, Zhang X. A robust 6-lncRNA prognostic signature for predicting the prognosis of patients with colorectal cancer metastasis. Front Med (Lausanne). 2020;7:56.</Citation></Reference><Reference><Citation>Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330&#x2013;337.</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344&#x2013;349.</Citation></Reference><Reference><Citation>Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401&#x2013;404.</Citation></Reference><Reference><Citation>Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.</Citation></Reference><Reference><Citation>Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more &#x201c;personalized&#x201d; approach to cancer staging. CA Cancer J Clin. 2017;67:93&#x2013;99.</Citation></Reference><Reference><Citation>Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.</Citation></Reference><Reference><Citation>Wang W, Li Q, Yang T, et al. Expression of AQP5 and AQP8 in human colorectal carcinoma and their clinical significance. World J Surg Oncol. 2012;10:242.</Citation></Reference><Reference><Citation>Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review. Diagn Pathol. 2014;9:221.</Citation></Reference><Reference><Citation>Gibson-Corley KN, Olivier AK, Meyerholz DK. Principles for valid histopathologic scoring in research. Vet Pathol. 2013;50:1007&#x2013;1015.</Citation></Reference><Reference><Citation>R Studio Team. RStudio: Integrated Development for R. Boston, MA: RStudio, Inc; 2016.</Citation></Reference><Reference><Citation>R Core Team. R: a language and environment for statistical computing. Vienna, Austria: Foundation for Statistical Computing; 2018.</Citation></Reference><Reference><Citation>Carter JV, Roberts HL, Pan J, et al. A highly predictive model for diagnosis of colorectal neoplasms using plasma microRNA: improving specificity and sensitivity. Ann Surg. 2016;264:575&#x2013;584.</Citation></Reference><Reference><Citation>O&#x2019;Brien SJ, Carter JV, Burton JF, et al. The role of the miR-200 family in epithelial-mesenchymal transition in colorectal cancer: a systematic review. Int J Cancer. 2018;142:2501&#x2013;2511.</Citation></Reference><Reference><Citation>Rice J, Roberts H, Burton J, et al. Assay reproducibility in clinical studies of plasma miRNA. PLoS One. 2015;10:e0121948.</Citation></Reference><Reference><Citation>Trigueros-Motos L, P&#xe9;rez-Torras S, Casado FJ, Molina-Arcas M, Pastor-Anglada M. Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs. BMC Cancer. 2012;12:434.</Citation></Reference><Reference><Citation>Kim KS, Kim JE, Choi KJ, Bae S, Kim DH. Characterization of DNA damage-induced cellular senescence by ionizing radiation in endothelial cells. Int J Radiat Biol. 2014;90:71&#x2013;80.</Citation></Reference><Reference><Citation>Marks KM, West NP, Morris E, Quirke P. Clinicopathological, genomic and immunological factors in colorectal cancer prognosis. Br J Surg. 2018;105:e99&#x2013;e109.</Citation></Reference><Reference><Citation>Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer. 2000;88:1739&#x2013;1757.</Citation></Reference><Reference><Citation>Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92:434&#x2013;444.</Citation></Reference><Reference><Citation>Huang D, Sun W, Zhou Y, et al. Mutations of key driver genes in colorectal cancer progression and metastasis. Cancer Metastasis Rev. 2018;37:173&#x2013;187.</Citation></Reference><Reference><Citation>Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:979&#x2013;994.</Citation></Reference><Reference><Citation>Reynolds IS, Furney SJ, Kay EW, McNamara DA, Prehn JHM, Burke JP. Meta-analysis of the molecular associations of mucinous colorectal cancer. Br J Surg. 2019;106:682&#x2013;691.</Citation></Reference><Reference><Citation>Winter DC, Sund M. Cancer surgery in the genomic era. Br J Surg. 2018;105:e12&#x2013;e13.</Citation></Reference><Reference><Citation>Wu Q, Yang ZF, Wang KJ, et al. AQP8 inhibits colorectal cancer growth and metastasis by down-regulating PI3K/AKT signaling and PCDH7 expression. Am J Cancer Res. 2018;8:266&#x2013;279.</Citation></Reference><Reference><Citation>Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38:11&#x2013;19.</Citation></Reference><Reference><Citation>Sahin IH, Akce M, Alese O, et al. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019;121:809&#x2013;818.</Citation></Reference><Reference><Citation>Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018;24:3834&#x2013;3848.</Citation></Reference><Reference><Citation>Zhang L, Zhao Y, Dai Y, et al. Immune landscape of colorectal cancer tumor microenvironment from different primary tumor location. Front Immunol. 2018;9:1578.</Citation></Reference><Reference><Citation>Bojmar L, Karlsson E, Elleg&#xe5;rd S, et al. The role of microRNA-200 in progression of human colorectal and breast cancer. PLoS One. 2013;8:e84815.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31567920</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Naples Prognostic Score Is a Useful Prognostic Marker in Patients With Metastatic Colorectal Cancer.</ArticleTitle><Pagination><StartPage>1485</StartPage><EndPage>1493</EndPage><MedlinePgn>1485-1493</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001484</ELocationID><Abstract><AbstractText Label="BACKGROUND">Systemic inflammation may influence the response to systemic chemotherapy or the prognosis in patients with various cancers. The Naples prognostic score, based on inflammatory and nutritional statuses, is a useful prognostic marker in patients undergoing surgery for colorectal cancer; however, its significance in patients with metastatic colorectal cancer remains unclear.</AbstractText><AbstractText Label="OBJECTIVE">We aimed to evaluate the prognostic significance of the Naples prognostic factor in patients with metastatic colorectal cancer receiving first-line chemotherapy and to compare its prognostic accuracy with the neutrophil:lymphocyte ratio, platelet:lymphocyte ratio, and the systemic immune-inflammatory index.</AbstractText><AbstractText Label="DESIGN">This was a retrospective study of prospectively collected data.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a university hospital.</AbstractText><AbstractText Label="PATIENTS">A total of 259 patients received first-line systemic chemotherapy for metastatic colorectal cancer.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The Naples prognostic score was calculated by a composite score of albumin and cholesterol concentrations, lymphocyte:monocyte ratio, and neutrophil:lymphocyte ratio. The patients were divided into 3 groups based on increasing Naples scores (groups 0-2), and the associations of the Naples prognostic score with clinicopathologic features and overall survival were evaluated.</AbstractText><AbstractText Label="RESULTS">Higher Naples prognostic score was positively associated with right-sided primary tumors and synchronous metastases and negatively with primary tumor resection. Patients in group 2 (high Naples prognostic score) had significantly shorter overall survival than those in groups 0 and 1 (p = 0.012 and 0.022). Multivariate Cox regression analysis identified the Naples prognostic score as an independent prognostic factor for overall survival (HR = 1.574; p = 0.004). Time-dependent receiver operating characteristic curve analysis showed that Naples prognostic score was more sensitive than other prognostic factors for predicting overall survival.</AbstractText><AbstractText Label="LIMITATIONS">The main limitations are the sample size, single institutional feature, and treatment heterogeneity.</AbstractText><AbstractText Label="CONCLUSIONS">The Naples prognostic score may be a useful prognostic marker in patients with metastatic colorectal cancer receiving systemic chemotherapy. See Video Abstract at http://links.lww.com/DCR/B72. LA PUNTUACI&#xd3;N PRON&#xd3;STICA DE N&#xc1;POLES ES UN MARCADOR PRON&#xd3;STICO &#xda;TIL EN PACIENTES CON C&#xc1;NCER COLORRECTAL METAST&#xc1;SICO: La inflamaci&#xf3;n sist&#xe9;mica puede influir en la respuesta a la quimioterapia sist&#xe9;mica o el pron&#xf3;stico en pacientes con varios tipos de c&#xe1;ncer. La puntuaci&#xf3;n pron&#xf3;stica de N&#xe1;poles, basada en estados inflamatorios y nutricionales, es un marcador pron&#xf3;stico &#xfa;til en pacientes sometidos a cirug&#xed;a por c&#xe1;ncer colorrectal; sin embargo, su importancia en pacientes con c&#xe1;ncer colorrectal metast&#xe1;sico sigue siendo incierta.El objetivo fue evaluar la importancia pron&#xf3;stica del factor pron&#xf3;stico de N&#xe1;poles en pacientes con c&#xe1;ncer colorrectal metast&#xe1;sico que reciben quimioterapia de primera l&#xed;nea y comparar su precisi&#xf3;n pron&#xf3;stica con la relaci&#xf3;n neutr&#xf3;filos: linfocitos, plaquetas: linfocitos y el &#xed;ndice sist&#xe9;mico inmune-inflamatorio.Este estudio se realiz&#xf3; en un hospital universitario.Este fue un estudio retrospectivo de datos recolectados prospectivamente.Un total de 259 pacientes recibieron quimioterapia sist&#xe9;mica de primera l&#xed;nea para el c&#xe1;ncer colorrectal metast&#xe1;sico.La puntuaci&#xf3;n pron&#xf3;stica de N&#xe1;poles se calcul&#xf3; mediante una puntuaci&#xf3;n compuesta de concentraciones de alb&#xfa;mina y colesterol, proporci&#xf3;n de linfocitos: monocitos y proporci&#xf3;n de neutr&#xf3;filos: linfocitos. Los pacientes se dividieron en tres grupos basados en el aumento de las puntuaciones de N&#xe1;poles (grupos 0-2, respectivamente) y se evaluaron las asociaciones de la puntuaci&#xf3;n pron&#xf3;stica de N&#xe1;poles con las caracter&#xed;sticas cl&#xed;nico-patol&#xf3;gicas y la supervivencia general.La puntuaci&#xf3;n pron&#xf3;stica de N&#xe1;poles es m&#xe1;s alta se asoci&#xf3; positivamente con los tumores primarios del lado derecho y met&#xe1;stasis sincr&#xf3;nicas, y negativamente con la resecci&#xf3;n del tumor primario. Los pacientes del grupo 2 (alto puntaje pron&#xf3;stico de N&#xe1;poles) tuvieron una supervivencia general significativamente menor que los de los grupos 0 y 1 (p = 0.012 y 0.022, respectivamente). El an&#xe1;lisis de regresi&#xf3;n de Cox multivariado identific&#xf3; la puntuaci&#xf3;n pron&#xf3;stica de N&#xe1;poles como un factor pron&#xf3;stico independiente para la supervivencia global (&#xed;ndice de riesgo = 1.574; p = 0.004). El an&#xe1;lisis de la curva caracter&#xed;stica de funcionamiento del receptor dependiente del tiempo mostr&#xf3; que la puntuaci&#xf3;n pron&#xf3;stica de N&#xe1;poles era m&#xe1;s sensible que otros factores pron&#xf3;sticos para predecir la supervivencia global.Las principales limitaciones son el tama&#xf1;o de la muestra, la caracter&#xed;stica institucional &#xfa;nica y la heterogeneidad del tratamiento.La puntuaci&#xf3;n pron&#xf3;stica de N&#xe1;poles puede ser un marcador pron&#xf3;stico &#xfa;til en pacientes con c&#xe1;ncer colorrectal metast&#xe1;sico que reciben quimioterapia sist&#xe9;mica. Vea el Abstract del video en http://links.lww.com/DCR/B72.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiyoshi</LastName><ForeName>Yukiharu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Daitoku</LastName><ForeName>Nobuya</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Okadome</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yamashita</LastName><ForeName>Kohei</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kuroda</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sawayama</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Iwatsuki</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Baba</LastName><ForeName>Yoshifumi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Naoya</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Baba</LastName><ForeName>Hideo</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>ZIF514RVZR</RegistryNumber><NameOfSubstance UI="D000075462">Serum Albumin, Human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004358" MajorTopicYN="N">Drug Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009752" MajorTopicYN="Y">Nutritional Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010976" MajorTopicYN="N">Platelet Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075462" MajorTopicYN="N">Serum Albumin, Human</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31567920</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001484</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>